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Drugs that enhance GABAergic inhibition alleviate inflammatory and neuropathic pain after spinal application. This antihyperalgesia
occurs mainly through GABAA receptors (GABAARs) containing a2 subunits (a2-GABAARs). Previous work indicates that potentiation
of these receptors in the spinal cord evokes profound antihyperalgesia also after systemic administration, but possible synergistic or
antagonistic actions of supraspinal a2-GABAARs on spinal antihyperalgesia have not yet been addressed. Here we generated two lines of
GABAAR-mutated mice, which either lack a2-GABAARs specifically from the spinal cord, or, which express only benzodiazepine-
insensitive a2-GABAARs at this site. We analyzed the consequences of these mutations for antihyperalgesia evoked by systemic
treatment with the novel non-sedative benzodiazepine site agonist HZ166 in neuropathic and inflammatory pain. Wild-type mice and
both types of mutated mice had similar baseline nociceptive sensitivities and developed similar hyperalgesia. However, antihyperalgesia by
systemic HZ166 was reduced in both mutated mouse lines by about 60% and was virtually indistinguishable from that of global point-
mutated mice, in which all a2-GABAARs were benzodiazepine insensitive. The major (a2-dependent) component of GABAAR-mediated
antihyperalgesia was therefore exclusively of spinal origin, whereas supraspinal a2-GABAARs had neither synergistic nor antagonistic
effects on antihyperalgesia. Our results thus indicate that drugs that specifically target a2-GABAARs exert their antihyperalgesic effect
through enhanced spinal nociceptive control. Such drugs may therefore be well-suited for the systemic treatment of different chronic
pain conditions.
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INTRODUCTION
Chronic neuropathic pain syndromes are frequently un-
responsive to classical analgesic drugs including cyclooxy-
genase inhibitors and opioids. Drugs most effective in
these pain conditions include anticonvulsant drugs that
modulate or block voltage-gated Na
þ or Ca
2þ channels
(Sang and Hayes, 2006). Other anticonvulsive drugs with a
different mode of action include the benzodiazepine site
agonists, which enhance neuronal inhibition through
facilitation of GABAA receptor-mediated neurotransmis-
sion. Diminished GABAergic or glycinergic inhibition in the
spinal dorsal horn (ie, in the sensory part of the spinal cord)
has been shown to be a major contributor to chronic
pain syndromes (Ahmadi et al, 2002; Coull et al, 2003;
Harvey et al, 2004), suggesting that drugs that facilitate
spinal inhibition might correct a major component of the
maladaptive neuroplasticity underlying chronic pain states.
In line with this concept, previous work has shown that
spinal injection of benzodiazepine site agonists provides
pain relief in a number of rodent models of inflammatory
and neuropathic pain (Knabl et al, 2008; Luger et al, 1995;
Witschi et al, 2011).
Mammalian GABAARs form a heterogeneous family of
heteropentameric ion channels assembled from a repertoire
of 19 subunits. The most prevalent subtypes of GABAARs
contain two a-, two b- and one g2- subunits. Pharmacolo-
gical properties of the different GABAAR subtypes are best
characterized by the type of a-subunit present in the indi-
vidual receptors (Olsen and Sieghart, 2008). Experiments
in genetically modified mice demonstrated a particular
relevance of GABAARs with an a2-type benzodiazepine
pharmacology (a2-GABAARs) for antihyperalgesia mediated
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These and subsequent experiments (Knabl et al, 2009)
established that the antihyperalgesic actions of benzodiaze-
pine site agonists occur independently from the sedative
action, which is mediated by a1-GABAARs (Rudolph et al,
1999). More recent experiments using novel benzodiazepine
site ligands with improved subunit specificity (ie, reduced
or absent activity at a1-GABAARs) have shown that such
novel compounds reduce nerve injury-induced and inflam-
mation-induced hyperalgesia also after systemic adminis-
tration (Di Lio et al, 2011; Knabl et al, 2008; Knabl et al,
2009; Munro et al, 2009; Munro et al, 2008; Reichl et al,
2012). While the contribution of spinal GABAARs to this
antihyperalgesia is likely, although still not formally proven,
the relevance of GABAAR subtypes in supraspinal circuits is
unclear. Such supraspinal GABAARs might contribute to
antihyperalgesia through a genuine antihyperalgesic effect,
eg, through GABAARs in the rostral agranular insular cortex
(Jasmin et al, 2003), or indirectly through the reversal
of anxiety-induced or stress-induced hyperalgesia (Andre
et al, 2005). The latter possibility is particularly relevant as
a2-GABAARs also contribute to benzodiazepine-mediated
anxiolysis (Lo ¨w et al, 2000; Morris et al, 2006). In contrast,
supraspinal GABAARs might also counteract spinal anti-
hyperalgesia through the silencing antinociceptive tracts
descending from the periaqueductal gray or the rostroven-
tromedial medulla (Harris and Westbrook, 1995; Luger
et al, 1995; Tatsuo et al, 1999). It is thus possible that
activation of supraspinal GABAARs either facilitates or
constrains spinal antihyperalgesia.
To address these questions, we have generated two lines
of GABAAR-mutated mice. The first line (hoxb8-a2
 / )
carries a tissue-specific deletion of the GABAAR a2 subunit
from all spinal neurons, astrocytes, and primary sensory
neurons up to the mid cervical level (approximately C4).
This tissue-specific ablation was achieved by crossing mice
that carried a GABAAR a2( Gabra2) allele flanked by two
loxP sites (a2
fl; Witschi et al, 2011) with mice expressing
the cre recombinase under the transcriptional control of
the hoxb8 homeobox gene (Witschi et al, 2010). The second
line can be viewed as a tissue-specific point-mutated
a2-GABAAR mouse line (hoxb8-a2
R/ ), which carries in
addition to one a2
fl allele, a benzodiazepine-insensitive
H101R point-mutated Gabra2 allele (a2
R;L o ¨w et al, 2000),
and the hoxb8-cre transgene. At supraspinal sites, this line
expresses the point-mutated allele together with a fully
functional (‘wild-type’) a2
fl allele, whereas in primary
sensory neurons and in the spinal nervous system only
the point-mutated allele is expressed. For pharmacological
analyses, we used the novel non-sedative 8-acetyleno-20-
pyridoimidazobenzodiazepine HZ166 (ethyl 8-ethynyl-6-
(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-
carboxylate, compound 2 in Rivas et al, 2009), which has
previously been shown to exhibit antihyperalgesic proper-
ties in the absence of sedation in mice (Di Lio et al, 2011).
Analysis of the antihyperalgesic effects of HZ166 in the two
mutated mouse lines and comparison of these effects with
those obtained in wild-type mice and in mice in which all
a2-GABAARs had been rendered benzodiazepine-insensitive
revealed that activation of supraspinal a2-GABAARs neither
exerts a positive nor a negative impact on the antihyper-
algesic actions of systemically applied HZ166.
MATERIALS AND METHODS
Generation of GABAAR-Mutated Mice
Three strains of GABAAR a2( gabra2)-mutated mice were
used to generate the genotypes needed for the present study:
(i) mice carrying GABAAR a2 alleles flanked by loxP sites
(a2
fl; Witschi et al, 2011), (ii) mice carrying a H101R point-
mutated ‘knock-in’ allele (a2
R;L o ¨w et al, 2000), and
(iii) hoxb8-cre transgenic mice (Witschi et al, 2010). Hoxb8-
a2
 /  mice and hoxb8-cre-negative (a2
fl/fl) littermates were
obtained from crossings of hoxb8-cre-positive a2
fl/fl mice
with a2
fl/fl mice. Hoxb8-a2
R/  mice and hoxb8-cre-negative
(a2
R/fl) littermates were generated by crossing hoxb8-cre-
positive a2
fl/fl mice with a2
R/R. All mouse lines had been
backcrossed to a C57BL/6J background for at least 10 gene-
rations and were maintained on this background through-
out the study. During the breeding of hoxb8-a2
 /  mice, a
small number of mice were born carrying a non-conditional
knockout allele of the gabra2 gene, which had occurred
through undesired recombination events in the germline.
To ensure that these mice were excluded from all
experiments and breeding, we verified the absence of the
knockout allele through PCR analyses performed on DNA
extracted from ear biopsies. This tissue was chosen because
analysis of hoxb8-cre ROSA26-lacZ double transgenic
reporter mice had demonstrated that hoxb8-cre was not
expressed in outer ear tissue at any developmental stage.
Morphology
Distribution of GABAAR a2 protein was studied in brain
and spinal cord sections obtained from adult hoxb8-a2
 / 
and hoxb8-a2
R/– mice and from hoxb8-cre
  littermates
(a2
fl/fl and a2
R/fl mice). For immunoperoxidase stainings,
a polyclonal antibody directed against the N-terminal
nine amino acids (NIQEDEAKN) of the GABAAR a2 subunit
(Fritschy and Mo ¨hler, 1995) was used as the primary
antibody. Stainings (triplicates) were made as described
previously (Paul et al, 2012). Sections from GABAA
receptor-mutated mice and from control littermates were
treated in a strictly parallel fashion.
Quantitative reverse Transcriptase PCR
Four to six lumbar spinal cords, lumbar DRGs, and
hippocampi were rapidly removed from euthanized adult
hoxb8-a2
 /  mice and a2
fl/fl littermates. mRNA was trans-
cribed into cDNA using the QuantiTect Reverse Transcrip-
tion Kit (Qiagen no.205311). Expression of GABAAR
subunits was assessed using b-actin as reference gene (for
details of the assays see Witschi et al (2011)).
[
3H]Ro 15-4513 Binding Assay
HEK293 cells maintained in DMEM/10% FBS in poly-
lysine-coated culture dishes (10cm) were transfected with
plasmids containing the subunit combination a2b3g2o r
a2(H101R)b3g2 (7mg total DNA, ratio 1:1:2) using jetPEI
transfection reagent (Polyplus-transfection). Twenty-four
hours after transfection, HEK293 cells were collected in PBS.
HEK293 cells were homogenized in 10 vol 10mM Tris pH
7.5, 0.32M sucrose, protease inhibitor cocktail (complete
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NeuropsychopharmacologyMini, Roche Applied Science) and centrifuged at 1000g
for 10min. The supernatant was carefully removed
and centrifuged at 41C again for 20min at 25000g
at 41C. The crude membrane pellet was resuspended in
10mM Tris-HCl pH 7.4, protease inhibitor cocktail and
washed once by centrifugation and re-suspension. Aliquots
of the crude membranes prepared from HEK293 cells
expressing the a2b3g2o ra2(H101R)b3g2 subunit combina-
tion (150–200mg protein) were incubated with increa-
sing concentrations of HZ166 (10
 8–10
 4
M) and 6.3nM
[
3H]Ro 15-4513 (22.7Ci/mmol, PerkinElmer) in a total
volume of 200ml for 90min on ice. Subsequently,
the samples were filtered onto glass fiber filters using a
12-channnel semiautomated cell harvester (Scatron) and
washed with ice-cold buffer (10mM Tris-HCl pH 7.4). Non-
specific [
3H]Ro 15-4513 binding was measured using 10mM
flumazenil. The radioactivity of the filters was determined
by liquid scintillation counting using a Tricarb 2500 liquid
scintillation analyzer. Binding data were analyzed using the
GraphPad Prism software (version 5.02, GraphPad Software,
USA).
Electrophysiological Analyses
The effects of HZ166 on GABAARs were studied in HEK293
cells transiently expressing GABAARs and in spinal cord
slices of hoxb8-a2
 /  mice and wild-type (hoxb8-cre-
negative a2
fl/fl) littermates. HEK293 cells were transfected
with rat a2/a2(H101R), b3 and g2 GABAAR expression
vectors (Benson et al, 1998) using lipofectamine LTX
(Invitrogen). The transfection mixture contained (in mg) 1
a2/b3, 3 g2 and 0.5 EGFP (used as a marker of successful
transfection). Recordings were made 18–36hours after
transfection. Whole-cell patch-clamp recordings of GABA-
evoked currents were made at room temperature (20–241C)
and at a holding potential of  60mV. The external solution
contained (in mM) 150 NaCl, 10 KCl, 2.0 CaCl2, 1.0 MgCl2,
10 HEPES (pH 7.4), and 10 glucose. Recording electrodes
were filled with internal solution containing (in mM) 120
CsCl, 10 EGTA, 10 HEPES (pH 7.40), 4 MgCl2, 0.5 GTP, and
2 ATP. CsCl was used instead of KCl to block GABAB
receptor-evoked K
þ currents. GABA was applied to the
recorded cell using a manually controlled pulse (4–6s) of a
low subsaturating GABA concentration (EC5). GABA EC5
values were determined for wild-type a2b3g2 and mutant
a2(H101R)b3g2 receptors separately. EC50 values and Hill
coefficients (nh) were obtained from fits of normalized
concentration–response curves to the equation IGABA¼Imax
[GABA]nh/([GABA]nhþ[EC50]nh). Imax was determined as
the current elicited by a saturating concentration of GABA
(500mM). HZ166 was co-applied together with GABA
without preincubation.
Transverse spinal cord slices were prepared from 2- to
3-week-old mice of either sex as described previously
(Ahmadi et al, 2002). Slices were kept in oxygenated (95%
O2/5% CO2) external solution containing (in mM) 120 NaCl,
5 HEPES, 26 NaHCO3, 1.25 NaH2PO4, 2.5 KCl, 2 CaCl2,1
MgCl2, and 10 glucose (pH 7.35) at 351C. Superficial dorsal
horn neurons were visually identified using an infrared
gradient contrast equipment. Whole-cell patch-clamp
recordings were performed at room temperature at a hold-
ing potential of  60mV. Patch pipettes were filled with
internal solution containing (in mM) 120 CsCl, 10 EGTA, 4
MgCl2, 0.5 GTP, 2 ATP, and 10 HEPES (pH 7.30 adjusted
with CsOH). QX-314 (5mM) was added to block voltage-
activated Na
þ currents in the recorded cell. Slices were
continuously superfused with oxygenated external solution
at a flow rate of 1.3–1.6ml/min. After 4–5min of baseline
recording, GABA (50mM) was bath-applied. Steady-state
GABA-evoked currents were achieved usually 3–5min after
application. Subsequently, HZ166 (10mM) was co-applied
with the same GABA concentration for 6 to 7min. After-
ward, GABA and HZ166 were washed-out, or bicuculline
(20mM) was applied. Recordings in which recovery to
baseline currents before GABA application was less than
85–90% were excluded from the analysis.
Behavioral Testing
Experiments were performed in 7- to 10-week-old male and
female mice. Care was taken to ensure equal numbers of
age-matched male and female mice in all experi-
ments. Mechanical and thermal nociceptive sensitivities of
hoxb8-a2
 /  and of hoxb8-cre-negative a2
fl/fl littermates
were determined using electronic von Frey filaments and
the plantar test, respectively (for details see Witschi et al,
2011).
Antihyperalgesic properties of HZ166 were studied in two
models: (i) activity against neuropathic hyperalgesia was
assessed in the chronic constriction injury (CCI) model
(Bennett and Xie, 1988); unilateral constriction of the left
sciatic nerve was performed as described previously (Ho ¨sl
et al, 2006) and (ii) inflammation was evoked through
subcutaneous injection of zymosan A (0.06mg in 20ml
saline (0.9% NaCl)) into one hindpaw. HZ166 was tested 7
days after CCI surgery or 48h after zymosan A injection,
when sensitization had reached a maximum (Witschi et al,
2011). Sensitivities of the injured/inflamed paw and of the
contralateral control paw were measured alternately and
at least five measurements were taken per mouse and time
point. Antihyperalgesia was quantified for the time interval
of 60–90min post drug injection, when the drug effect was
maximal, and expressed as percent maximum pos-
sible analgesia¼(Rpost-drug Rpre-drug)/(Rbaseline Rpre-drug) 
100%, where R is the average response latency or threshold
under baseline condition (Rbaseline), after induction of neuro-
pathy or inflammation but before drug injection (Rpre-drug),
and 60–90min after drug injection (Rpost-drug).
Locomotor activity was assessed as described before
(Di Lio et al, 2011). HZ166 was administered immediately
before placing the mice into the open field arena, and the
number of beam crosses per 24min was determined for a
total of 96min after drug administration.
Motor coordination of hoxb8-a2
 /  and of hoxb8-cre-
negative a2
fl/fl littermates was investigated in the rotarod
test either at two fixed rotational speeds (5 and 10r.p.m.)
for analysis of baseline motor coordination, or with
increasing rotational velocity (from 4r.p.m. to 40r.p.m.
within 5min) for the analysis of effects of HZ166 on motor
coordination. Each mouse was tested three times. HZ166
was given 60min before testing on the rotarod. Permission
for the animal experiments was obtained from the
Veterina ¨ramt des Kantons Zu ¨rich (ref. no. 135/2009).
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To assess a possible influence of supraspinal a2-GABAARs
to GABAergic analgesia, three prerequisites were needed:
(i) mice that express benzodiazepine-sensitive a2-GABAARs
only in the brain, (ii) a benzodiazepine site agonist that
causes significant antihyperalgesia after systemic adminis-
tration at doses that do not produce confounding sedation
or motor impairment, and (iii) we needed to demonstrate
that the facilitating action of this agonist on a2-GABAARs
was lost in H101R point-mutated receptors.
In order to reach the first prerequisite, we generated two
lines of a2-GABAAR-mutated mice using the cre/loxP
system. The first line lacked the GABAAR a2 subunit from
the spinal cord and from all primary sensory neurons
(hoxb8-a2
 / ), but showed unchanged GABAAR a2 sub-
unit expression in the brain. These mice carried a hoxb8-cre
transgene and two floxed GABAAR a2( a2
fl) alleles. The
second line was a conditional point-mutated (hoxb8-a2
R/–)
mouse line, whose spinal a2-GABAARs were rendered
benzodiazepine insensitive. These mice carried the hoxb8-
cre transgene together with a a2
fl allele and a point-mutated
(H101R) GABAAR a2( a2
R) allele. Morphological analyses
demonstrated that the supraspinal GABAAR a2 subunit
distribution of hoxb8-a2
 /  mice was indistinguishable
from that of a2
fl/fl (wild-type) littermates (Figure 1a).
However, transverse sections of the lower lumbar spinal
cord of hoxb8-a2
 /  mice did not show any GABAAR a2
subunit immunoreactivity, indicating highly effective
hoxb8-cre-mediated gene recombination. Sagittal sections
of the cervical spinal cord revealed the expected progressive
rostral to caudal loss of GABAAR a2 subunit expression
within the upper cervical segments (not shown). The
apparent lack of a2-GABAARs from the lumbar spinal cord
of hoxb8-a2
 /  mice indicates that only few, if any, spinal
a2-GABAARs reside on processes of neurons descending
from supraspinal areas. In conditional point-mutated
(hoxb8-a2
R/-) mice and hoxb8-cre-negative (a2
R/fl) litter-
mates, no differences in a2-subunit immunoreactivity were
observed in either the brain or the spinal cord (Figure 1b),
suggesting that the loss of one allele had no apparent effect
on the amount of GABAAR a2 subunit expressed.
To further corroborate the loss of GABAAR a2 gene
expression and to assess possible compensatory changes in
the expression of other GABAAR a-subunits, we performed
qRT-PCR analyses from lumbar DRGs, lumbar spinal cords,
and hippocampi of hoxb8-a2
 /  mice and hoxb8-cre-
negative a2
fl/fl (wild-type) littermates (Figure 1c). In all
three tissues, we detected mRNA encoding for GABAAR
a1–a5 subunits, but no a6 subunit mRNA. As expected, the
a2 subunit was the most extensively expressed GABAAR
a-subunit in the lumbar spinal cords and DRGs. Its
expression was completely lost in lumbar DRGs and spinal
Figure 1 GABAAR a2-subunit distribution in brains and spinal cords of hoxb8-a2
 /  and hoxb8-a2
R/fl mice and changes in GABAAR a-subunit
expression. (a, b), immunoperoxidase staining of GABAAR a2 subunits in horizontal sections of the lumbar spinal dorsal horn and in sagittal brain sections of
spinal cord-specific GABAAR a2-knockout (hoxb8-a2
 / ) and a2(H101R)-knock-in mice (hoxb8-a2
R/-). Bottom row, sections obtained from the respective
control littermates (hoxb8-cre-negative wild-type and a2
R/fl). Similar results were obtained from at least two additional mice of each genotype. Scale bars are
200mm (dorsal horn) and 1mm (brain), and apply to all sections. (c) Quantitative reverse transcriptase PCR measurements of all six GABAAR a-subunits in
lumbar DRGs, lumbar spinal cords, and hippocampi of hoxb8-a2
 /  and a2
fl/fl littermates. mRNA expression relative to b-actin (mean±SEM, n¼6–7 mice
per genotype and tissue). mRNA encoding for a6 GABAAR subunit was not detectable in any of the three tissues. ***Po0.001, P40.13 for all other
comparisons, ANOVA followed by Bonferroni post hoc correction for 18 independent pair-wise comparisons.
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 /  mice, but remained unchanged in
the hippocampus. No significant changes were seen in the
expression of the other GABAAR a subunits in any of the
three tissues. For spinal cord and DRG tissue, we also
analyzed the expression of r1, r2, and r3 subunit genes,
which are able to form functional, benzodiazepine-insensi-
tive GABAA (or sometimes also called GABAC) receptors.
Expression of r-subunits was unchanged in hoxb8-a2
 / 
mice (data not shown).
In order to assess the contribution of supraspinal a2-
GABAARs to benzodiazepine-mediated antihyperalgesia, we
used the new non-sedative partial benzodiazepine site
agonist HZ166 (Rivas et al, 2009), which exerts pronounced
antihyperalgesic actions in mice in the absence of sedation
(Di Lio et al, 2011). Among the different available com-
pounds with improved subtype specificity, we chose HZ166
because it possesses higher intrinsic activity at a2-GABAARs
than for example TPA023 (Atack et al, 2006) or NS 11394
(Mirza et al, 2008), and has better pharmacokinetic proper-
ties in mice than L-838,417 (Scott-Stevens et al, 2005).
Before we analyzed its antihyperalgesic actions in GABAAR-
mutated mice, we had to verify that the H101R point
mutation abolished modulation by HZ166. Although it has
previously been shown that this mutation dramatically
reduces the binding of and facilitation by diazepam
(Wieland et al, 1992), it can have different effects on the
action of other benzodiazepine site ligands. The potentiat-
ing effect of bretazenil for example is enhanced in the point-
mutated receptors, and the action of Ro 45-1513 is
converted from negative to positive modulation (Benson
et al, 1998). We therefore compared the binding affinity of
HZ166 with wild-type a2/b3/g2 and point-mutated
a2(H101R)/b3/g2-GABAARs (Figure 2a). In wild-type a2/
b3/g2-GABAARs, HZ166 displaced [
3H] Ro 45-1513 binding
with a Ki of 221±22nM (mean±SEM, n¼4). In a2(H101R)/
b3/g2 point-mutated receptors competition was abolished at
HZ166 concentration p10mM. Only at 100mM, a small
displacement was detected (26±3%, mean±SEM, n¼4).
Subsequent electrophysiological experiments in HEK293
cells transfected with either wild-type or point-mutated
a2(H101R)/b3/g2 GABAARs verified that both receptors
responded similarly to GABA (Figure 2b). We then
investigated the impact of the point mutation on potentia-
tion of a2/b3/g2 GABAARs by HZ166 and showed that
HZ166 completely lost its ability for positive allosteric
modulation in the point-mutated receptors (Figure 2c–e).
Although HZ166 potentiated GABA-evoked currents
through wild-type receptors by 232±20% (HZ166, 5mM,
n¼8), potentiation was virtually absent in the point-
mutated receptors at HZ166 concentrations p1mM and
reached only 17.6±2.4% at 5mM (n¼7; Po0.001 un-
paired student t-test, wild-type vs point-mutated receptors).
Before proceeding to behavioral experiments, we also
investigated the impact of hoxb8-cre-mediated ablation of
GABAAR a2 subunits on the amplitude of native GABAARs
in the spinal dorsal horn and on their sensitivity to HZ166
(Figure 3). To this end, we used lumbar spinal cord slices
and recorded GABAergic membrane currents from neurons
located in the superficial dorsal horn of hoxb8-a2
 / 
mice and of wild-type (a2
fl/fl) littermates. Superfusion
Figure 2 HZ166 binding properties to recombinant wild-type and a2(H101R)b3g2-GABAARs and potentiation by HZ166. (a) Binding affinity of HZ166
to wild-type and a2(H101R)b3g2 point-mutated GABAARs determined by [
3H] Ro15-4513 displacement. Ki in wild-type GABAARs was 221±22nM
(mean±SEM, n¼4). (b–e) Electrophysiological analyses (e). (b) Activation of wild-type and a2(H101R)b3g2 GABAARs exhibited similar dependence on
GABA concentration. EC50 was 27±1mM (mean±SEM, n¼8) and 40±2mM (n¼7) for wild-type and a2(H101R)b3g2 point-mutated GABAARs,
respectively. Hill coefficients were 1.2±0.03 and 1.4±0.07, and maximum currents were 3.6±0.4 nA and 3.5±0.7 nA. (c–e) Potentiation by HZ166.
(c) Example of current traces evoked by GABA (EC5¼5mM) in the presence or absence of HZ166 (1mM). (d) Concentration–response curves of wild-type
and a2(H101R)b3g2 point-mutated GABAARs for HZ166. EC50 of HZ166 for wild-type GABAARs: 217±20nM. (e) Statistical comparison of potentiation
by HZ166 (1mM). ***Po0.001 (wild-type vs point-mutated receptors), unpaired Student’s t-test.
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Neuropsychopharmacologyof the slices with 50mM GABA elicited average currents of
306±73 pA (mean±SEM, n¼6) in wild-type mice and
smaller currents in neurons of hoxb8-a2
 /  mice (153±20
pA, n¼8, P¼0.04, unpaired student t-test) (Figure 3a,b).
HZ166 (10mM) potentiated GABAAR currents in both
genotypes. However, potentiation was significantly smaller
in hoxb8-a2
 /  mice (52±14%, n¼8) than in wild-type
(a2
fl/fl) littermates (151±39%, n¼6, P¼0.02, unpaired
student t-test) (Figure 3c). Amplitudes of GABAAR currents
were thus reduced by about half, whereas potentiation by
HZ166 was reduced by two-thirds suggesting the presence
of both benzodiazepine (HZ166)-sensitive and benzodiaze-
pine (HZ166)-insensitive GABAAR current components in
spinal dorsal horn neurons. The retention of benzodiaze-
pine-sensitive GABAAR currents in hoxb8-a2
 /  mice is in
line with the results of our qRT-PCR experiments, which
had demonstrated the expression of three benzodiazepine-
sensitive GABAAR a-subunits (a1, a3, and a5) in addition to
a2 (Figure 1c). Conversely, unchanged expression of
r-subunits likely explains the reduced benzodiazepine
(HZ166) sensitivity of GABAAR currents in hoxb8-a2
 / 
mice.
We then went on to investigate hoxb8-a2
 /  and hoxb8-
a2
R/  mice in behavioral pain models and addressed their
susceptibility to antihyperalgesia by systemically applied
HZ166. The analysis of hoxb8-a2
R/  mice was particularly
interesting here because the unchanged expression of
a2-GABAARs in the spinal cord (compare Figure 1b) ren-
dered compensatory and adaptive changes highly unlikely.
In addition to hoxb8-a2
 /  mice and hoxb8-a2
R/  mice
(and their hoxb8-cre-negative littermates), we also included
homozygous point-mutated mice (a2
R/R). The comparison
of HZ166-induced antihyperalgesia in a2
R/R mice and in
wild-type mice allowed us to determine the total contribu-
tion of a2-GABAARs to antihyperalgesia by HZ166,
independent of their location. Conditional hoxb8-a2
 / 
knock-out mice and conditional hoxb8-a2
R/  knock-in
mice as well as the hoxb8-cre-negative (a2
fl/fl and a2
R/fl)
littermates and global a2
R/R point-mutated mice responded
similarly to mechanical stimulation of their hindpaws with
electronic von Frey filaments and to thermal stimulation
with defined radiant heat (Figure 4a–d). Neuropathic pain
sensitization induced through chronic constriction injury
(CCI) of the sciatic nerve, and inflammatory hyperalgesia
evoked by local subcutaneous zymosan A injection also
developed similarly in all genotypes (Figure 4a–d). As a
further control experiment, we assessed motor coordination
in hoxb8-a2
 /  and wild-type (a2
fl/fl) littermates in the
rotarod test at two different fixed rotational speeds (5 and
10 r.p.m.). Both lines managed to remain on the rotarod
for similar time periods (Figure 4e).
Finally, we addressed the antihyperalgesic action of
HZ166 against neuropathic pain in the three types of
mutant mice (hoxb8-a2
 / , hoxb8-a2
R/  and a2
R/R mice)
and in the hoxb8-cre-negative wild-type (a2
fl/fl) and a2
R/fl
littermates. For these experiments, we chose a dose of
16mg/kg body weight applied intraperitoneally (i.p.), which
has previously been shown to produce a saturating
antihyperalgesic response in the absence of confounding
sedation or motor impairment (Di Lio et al, 2011). We first
verified that this dose of HZ166 had no effect on motor
coordination or locomotor activity in neuropathic mice
(Figure 5a–c). We then tested the effects of HZ166 against
mechanical and thermal hyperalgesia in neuropathic mice
(Figure 5d–g). The antihyperalgesic drug response reached
a maximum between 60 and 90min after drug injection
(Figure 5d and f). This time interval was subsequently used
to quantify HZ166-induced antihyperalgesia, expressed as
percent maximum possible effect (MPE). In wild-type
(hoxb8-cre-negative a2
fl/fl) mice, HZ166 reduced thermal
and mechanical hyperalgesia by 59.9±1.4% and 61.5±1.5%
of pre-drug values (% MPE, mean±SEM, n¼6, each)
(Figure 5e and g). Both the time course and the degree of
antihyperalgesia were very close to those reported pre-
viously by our group for wild-type C57BL/6J mice (Di Lio
et al, 2011). Antihyperalgesia by HZ166 was reduced in
a2
R/R mice to 24.7±3.6% and 26.6±7.0% of the maximum
possible effect (thermal and mechanical hyperalgesia,
Figure 3 Effects of HZ166 on GABA-evoked membrane currents in hoxb8-a2
 /  mice and in wild-type (a2
fl/fl) littermates. (a) Whole-cell voltage-clamp
recordings of GABA (50mM)-evoked membrane currents in superficial dorsal horn neurons of wild-type (a2
fl/fl) (top) and hoxb8-a2
 /  mice (bottom).
HZ166 (10mM) was coapplied together with GABA. Bicuculline (bic; 20mM) was added at the end of the experiment to verify that all currents measured
were GABAAR currents. (b, c) Statistical analysis of GABAAR current amplitudes (b) and of their potentiation by 10mM HZ166 (c). n¼6 and 8 cells for wild-
type (a2
fl/fl) and hoxb8-a2
 /  mice, respectively. *Po0.05, unpaired Student’s t-test.
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Neuropsychopharmacologyrespectively, n¼6, each), indicating that about 60% of the
antihyperalgesic actions of HZ166 were mediated by
a2-GABAARs. The degrees of antihyperalgesia observed in
both hoxb8-a2
 /  mice (24.0±5.1% and 25.0±5.1%, n¼6
each, for thermal and mechanical hyperalgesia, respectively)
and hoxb8-a2
R/  mice (27.4±5.1% and 26.4±5.2%, n¼6
each) were virtually indistinguishable from that in global
a2
R/R point-mutated mice, indicating that supraspinal
a2-GABAARs were not required for antihyperalgesia by
systemic HZ166. We also investigated antihyperalgesic pro-
perties of HZ166 against thermal inflammatory hyperalgesia
(Figure 5h). In wild-type (hoxb8-cre-negative a2
fl/fl) mice,
HZ166 reduced thermal hyperalgesia by 58.7±11.5%
(n¼7). This antihyperalgesia was almost lost in hoxb8-
a2
 /  mice (9.7±4.7%, n¼7) and in global a2-point-
mutated (a2
R/R) mice (3.8±0.2%, n¼7). Antihyperalgesia
against mechanical stimuli was relatively small in wild-
type mice (26.1±9.4%, n¼7) and almost completely lost
in hoxb8-a2
 /  mice (4.7±12.5%, n¼8). However, the
difference between wild-type and hoxb8-a2
 /  mice did
not reach statistical significance (P¼0.19) and effects of
conditional deletion or mutation of the a2 subunit were
therefore not further investigated.
The results of our experiments not only exclude that
analgesia or antihyperalgesia by HZ166 requires supraspinal
a2-GABAARs, but also render significant indirect effects
(such as reversal of anxiety or stress induced hyperalgesia)
through supraspinal a2-GABAARs unlikely. They thus
provide firm evidence for a genuine antihyperalgesic action
of systemically applied benzodiazepine site agonists
through a specific interaction with nociceptive circuits at
the spinal level.
DISCUSSION
Studies performed in mice carrying point-mutated benzo-
diazepine-insensitive GABAARs have allowed us to attribute
the different in vivo actions of benzodiazepines to distinct
GABAAR subtypes (Mo ¨hler et al, 2002). In the course of
these studies, it was shown that the sedative actions of
benzodiazepines depend on a1-GABAARs, (McKernan et al,
Figure 4 Characterization of baseline nociceptive sensitivity and of neuropathic and inflammatory hyperalgesia and of baseline motor coordination.
(a) Baseline heat sensitivity, and neuropathic (CCI) and inflammatory (zymosan A) heat hyperalgesia in hoxb8-a2
 /  mice (n¼13, 6, and 7, for naı ¨ve, CCI,
zymosan A-injected mice), in wild-type (a2
fl/fl) littermates (n¼27, 12, and 15), and in separately bred global a2
R/R point-mutated mice of the same genetic
background (n¼13, 6, and 7). P40.25, ANOVA followed by Bonferroni post hoc test. (b) Same as a, but spinal cord-specific a2(H101R) point-mutated
(hoxb8-a2
R/-) mice (n¼6, for both naı ¨ve and CCI mice) and hoxb8-cre-negative hoxb8-a2
R/fl littermates (n¼7, for both naı ¨ve and CCI mice). P40.26,
unpaired student t-test. (c, d) Same as a, b, but mechanical sensitivity and hyperalgesia. P40.51, ANOVA followed by Bonferroni post hoc test (c), and
P40.9 unpaired Student’s t-test (d). n¼6–7 mice, for all genotypes, pain models and tests. (e) Motor coordination assessed in the rotarod test. Time
(mean±SEM) for which the mouse managed to remain on the rod rotating at two different rotational velocities. Unpaired student’s t-test, P¼0.45, for
hoxb8-a2
 /  (n¼8) and wild-type (a2
fl/fl) littermates (n¼11), respectively.
Spinal GABAergic analgesia
J Paul et al
483
Neuropsychopharmacology2000; Rudolph et al, 1999), whereas the anxiolytic actions
were caused by a facilitation of a2-GABAARs (Lo ¨w et al,
2000). Other studies employing the same mouse lines
helped to establish additional, less obvious potential
indications for subtype-selective benzodiazepine site ago-
nists (Rudolph and Knoflach, 2011). One example of such a
previously unforeseen action is antihyperalgesia, ie, the
reversal of pathologically exaggerated sensitivity to pain.
Although several studies in rodents had suggested pain-
modulating actions of benzodiazepine site agonists, it has
been notoriously difficult to distinguish apparent analgesia
or antihyperalgesia from confounding sedation. Work with
GABAAR point-mutated mice provided for the first time
compelling evidence for a pain-relieving action of spinal
benzodiazepines and demonstrated a critical role of
a2-GABAARs in this process (Knabl et al, 2008). In these
experiments, pain relief manifested primarily in a reversal
of pathologically increased pain sensitivity rather than in
Figure 5 Locomotor activity, motor coordination and antihyperalgesia by HZ166 in a2-GABAA receptor-mutant mice. (a, b) Effects of HZ166 (16mg/kg
body weight i.p.) on locomotor activity in hoxb8-a2
 / , a2
fl/fl, a2
R/R mice with neuropathic hyperalgesia (7 days after CCI surgery). (a) Time course. Total
number of beam crosses (mean±SEM) per 24min over time (0–96min). (b) Statistical analysis. Two-way ANOVA followed by Bonferroni post hoc test.
Genotype treatment F(5,42)¼1.15, P¼0.35. (c) Same genotypes and treatments as in a,b, but effects on motor coordination. Time spent on an accelerating
rotarod (rotational velocity increasing from 4 r.p.m. to 40 r.p.m. within 5min) (s, mean±SEM). Genotype treatment F(5,42)¼0.36, P¼0.87. (d–g)
Antihyperalgesic actions of the same dose of HZ166 in conditional knock-out (hoxb8-a2
 / ) and conditional knock-in (hoxb8-a2
R/-) mice with neuropathic
hyperalgesia (7 days after CCI surgery). (d) Changes in heat hyperalgesia (paw withdrawal latency, s, mean±SEM) over time after HZ166 (16mg/kg) or
vehicle administration. (e) Statistical analysis. ANOVA followed by Bonferroni post hoc test. F(5,31)¼15.9. ***Po0.001 significant against vehicle.
þPo0.05,
and
þþþPo0.001 significantly different from hoxb8-cre-negative littermates. (f, g) Same as d, e, but mechanical hyperalgesia (paw withdrawal thresholds, g).
F(5,39)¼13.57.
þþPo0.01 significant against hoxb8-cre-negative littermates. (h) Same as e, but antihyperalgesic effects of HZ166 against inflammatory
heat hyperalgesia 48 hrs after zymosan A injection. F(3,25)¼17.4. Po0.001, significant against hoxb8-cre-negative littermates; ***Po0.001 significant against
vehicle.
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Neuropsychopharmacologyreduced responses to acute noxious stimuli, indicating that
spinal benzodiazepines exerted a hyperalgesic rather than a
genuine analgesic effect.
The availability of non-sedative benzodiazepine site
agonists suitable for systemic administration prompted
the question about a possible role in antihyperalgesia of
a2-GABAARs residing in supraspinal circuits. This appears
as an important issue because a2-GABAARs are not only
found in the spinal cord but also in supraspinal CNS areas
where they mediate for example the anxiolytic effects of
classical benzodiazepines (Lo ¨w et al, 2000). a2-GABAARs in
the brain might have contributed to benzodiazepine-
induced antihyperalgesia through a genuine effect on the
supraspinal nociceptive circuits, eg, in the rostral insular
cortex (Jasmin et al, 2003). Alternatively, their antihyper-
algesic effects could also have been secondary, reflecting eg,
a reversal of anxiety-induced hyperalgesia (Andre et al,
2005; Vidal and Jacob, 1982). Furthermore, supraspinal
GABAARs in the brainstem, in particular in the rostroven-
tromedial medulla, are known to inhibit antinociceptive
fiber tracts descending to the spinal cord and might thereby
produce a pronociceptive effect (Harris and Westbrook,
1995; Luger et al, 1995; Tatsuo et al, 1999). In the present
study, we have measured nociceptive withdrawal responses
to address these questions. Although these nociceptive
responses are primarily mediated by spinal circuits (ie, they
remain in spinalized animals, see for example Schouenborg
et al (1992)), they are highly susceptible to modulation by
supraspinal pain control centers, such as the rostral insular
cortex (Jasmin et al, 2003), the amygdala (Carrasquillo and
Gereau, 2007), the rostroventromedial medulla (Tatsuo
et al, 1999), and the periaqueductal gray (Harris and
Westbrook, 1995). As such, they are well-suited for
investigating the effects of supraspinal GABAA receptors
on hyperalgesia. In the present study, the actions of HZ166
on nociceptive withdrawal responses were nearly identical
in a2
R/R, hoxb8-a2
 /  and hoxb8-a2
R/  mice, indicating
that supraspinal a2-GABAARs did not have a detectable
influence on HZ166-mediated antihyperalgesia. The present
data therefore unambiguously demonstrate that the major
(ie, the a2-GABAAR-mediated) component of antihyper-
algesia by benzodiazepines occurs through a genuine effect
on the spinal cord and that this antihyperalgesia is not
secondary to effects of benzodiazepines on neuronal circuits
in the brain. Our results hence also disprove the possibi-
lity that a reversal of anxiety-induced or stress-induced
hyperalgesia contributed significantly to the antihyper-
algesia measured in our experiments.
Previous studies had used intrathecal injections of
diazepam or related benzodiazepines at the lumbar spinal
level to demonstrate pain-relieving actions of benzodiaze-
pines or of GABAAR agonists (reviewed in Zeilhofer et al,
2009). A critical role of a2-GABAARs in neuronal circuits of
the spinal cord was therefore likely, yet still not proven, as
the compounds injected might have reached supraspinal
sites through rostral diffusion. The present work establishes
that the spinal cord is the most relevant site for the
antihyperalgesic actions of benzodiazepine site agonists.
In a previous study, we have examined the contribution of
a subset of spinal a2-GABAARs, which reside on the central
terminals of primary nociceptive afferent fibers (Witschi
et al, 2011). This subset of a2-GABAARs was specifically
ablated through sns-cre-mediated gabra2 gene deletion. The
respective sns-a2
 /  mice were analyzed in the same
inflammatory and neuropathic pain models that have been
used in the present study. These previous experiments had
revealed that primary afferent a2-GABAARs make a partial
(about 50% of the total a2 component) contribution to
inflammatory antihyperalgesia. The present study shows
that the a2-GABAAR-mediated component of inflammatory
antihyperalgesia was completely lost in hoxb8-a2
 / 
mice and hence entirely of spinal origin. Analysis of the
sns-a2
 /  mice in neuropathic pain models had revealed
that a2-GABAARs on primary nociceptors did not make any
contribution to neuropathic antihyperalgesia. Again this
antihyperalgesic action was completely lost in hoxb8-a2
 / 
mice and therefore also exclusively of spinal origin. Early
in situ hybridization studies had found no a2-GABAARs on
intrinsic dorsal horn neurons (Persohn et al, 1991; Wisden
et al, 1991), but more recent work provided clear evidence
for the expression of these receptors by excitatory and
inhibitory neurons in the spinal dorsal horn (Paul et al,
2012), which is in line with the data presented here.
Subsequent to the discovery that a2-GABAARs are the
major target for the anxiolytic actions of benzodiazepines, a
significant number of benzodiazepine site agonists have
been developed which show reduced sedative properties
through improved a2 over a1 subtype selectivity (Rudolph
and Knoflach, 2011). These compounds allowed an assess-
ment of the potential analgesic and antihyperalgesic actions
of such compounds after systemic administration in wild-
type mice without confounding sedation. Studies testing
these newly developed compounds revealed significant
analgesic or antihyperalgesic properties in rodent pain models
(Di Lio et al, 2011; Knabl et al, 2008; Nickolls et al, 2011, for a
review see Zeilhofer et al, 2012). Comparison of the anti-
hyperalgesic efficacies of different compounds with their
pharmacological profiles at different GABAAR subtypes
suggests that a rather high intrinsic activity at a2-GABAARs
and a high a2o v e ra1 selectivity profile are necessary for
significant antihyperalgesia in the absence of sedation
(Zeilhofer et al, 2012). Although these results were consistent
with the findings obtained in the GABAAR point-mutated
mice discussed above, final proof that these antihyper-
algesic effects indeed originated from a2-GABAARs was
missing. Here we focused on one such compound, the novel
partial benzodiazepine site agonist HZ166. The present study
demonstrates that the antihyperalgesic actions of HZ166 were
to a large extent mediated by a2-GABAARs (about 90% and
60% for inflammatory and neuropathic hyperalgesia, respec-
tively).
Antihyperalgesia was not completely lost in the different
GABAAR a2-mutant mice investigated here. Depending on
the model used (ie, inflammatory or neuropathic hyper-
algesia), between 10 and 40% of the total antihyperalgesia
were retained in hoxb8-a2
 / , hoxb8-a2
R/ , and a2
R/R
mice. This is consistent with our previous study employing
intrathecal diazepam injections, where between 30 and 50%
of the antihyperalgesia remained in a2
R/R mice. At the
spinal level, this remaining component was mediated by
a3-GABAARs and/or a5-GABAARs (Knabl et al, 2008).
It is likely that these spinal receptors also account for the
antihyperalgesia retained in HZ166-treated hoxb8-a2
 / 
and hoxb8-a2
R/  mice. For a given benzodiazepine site
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Neuropsychopharmacologyagonist, the actual contribution of a2-GABAAR vs a3-
GABAARs and a5-GABAARs will depend on its potentiating
effects at these GABAAR subtypes. Until similar studies as
the present one have also been performed for a3- and a5-
GABAARs, it cannot be excluded that GABAARs different
from a2 (ie, a3-GABAARs and a5-GABAARs) also contribute
through a supraspinal site.
The present study provides strong evidence for a genuine
antihyperalgesic action of systemically applied non-sedative
benzodiazepine site agonists and demonstrates the pivotal
contribution of spinal cord circuits to this antihyperalgesia. A
critical role of inhibitory neurons and neurotransmitter
receptors in the spinal dorsal horn has been first proposed
in the gate control theory of pain (Melzack and Wall, 1965),
but attempts to translate this concept to pain therapy have
largely been unsuccessful. The present results show that an
enhancement of fast GABAergic inhibition in the spinal dorsal
horn is a possible strategy to reverse pathological hyper-
algesia. Provided that the results obtained with genetic mouse
mutants translate to the action of a2-GABAAR selective drugs
in humans, these agents should be devoid of sedation and
memory impairment (Rudolph and Knoflach, 2011). Con-
versely, it is likely that such drugs will exert in addition to
their antihyperalgesic actions also anxiolytic and possibly
muscle relaxant properties (Rudolph and Knoflach, 2011),
both of which should be beneficial to many chronic pain
patients. The present finding therefore provide additional
impetus for the development of subtype-selective benzodia-
zepine site agonists as novel antihyperalgesic agents.
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